Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes

NCT00343980 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00343980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Terminated
Start date
October 10, 2006
Completion date
March 10, 2008
Enrollment
363 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2